Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

In vitro and in vivo evaluation of human adenovirus type 49 as a vector for therapeutic applications

Bates, Emily A., Counsell, John R., Alizert, Sophie, Baker, Alexander T. ORCID:, Suff, Natalie, Boyle, Ashley, Bradshaw, Angela C., Waddington, Simon N., Nicklin, Stuart A., Baker, Andrew H. ORCID: and Parker, Alan L. ORCID: 2021. In vitro and in vivo evaluation of human adenovirus type 49 as a vector for therapeutic applications. Viruses 13 (8) , 1483. 10.3390/v13081483

[thumbnail of viruses-13-01483-v2.pdf] PDF - Published Version
Download (3MB)


The human adenovirus phylogenetic tree is split across seven species (A–G). Species D adenoviruses offer potential advantages for gene therapy applications, with low rates of pre-existing immunity detected across screened populations. However, many aspects of the basic virology of species D—such as their cellular tropism, receptor usage, and in vivo biodistribution profile—remain unknown. Here, we have characterized human adenovirus type 49 (HAdV-D49)—a relatively understudied species D member. We report that HAdV-D49 does not appear to use a single pathway to gain cell entry, but appears able to interact with various surface molecules for entry. As such, HAdV-D49 can transduce a broad range of cell types in vitro, with variable engagement of blood coagulation FX. Interestingly, when comparing in vivo biodistribution to adenovirus type 5, HAdV-D49 vectors show reduced liver targeting, whilst maintaining transduction of lung and spleen. Overall, this presents HAdV-D49 as a robust viral vector platform for ex vivo manipulation of human cells, and for in vivo applications where the therapeutic goal is to target the lung or gain access to immune cells in the spleen, whilst avoiding liver interactions, such as intravascular vaccine applications.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Publisher: MDPI
ISSN: 1999-4915
Funders: Cancer Research UK
Date of First Compliant Deposit: 2 August 2021
Date of Acceptance: 26 July 2021
Last Modified: 13 May 2023 21:01

Citation Data

Cited 3 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics